SkinBioTherapeutics plc (SBTX.L)

9.75 0.00 (0.00%) At close: 04:33PM BST

SkinBioTherapeutics plc

The Core
Bath Lane Newcastle Helix
Newcastle upon Tyne NE4 5TF
United Kingdom
44 19 1495 7325
https://www.skinbiotherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 11

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stuart John Ashman	CEO & Executive Director	371.1k	N/A	1966
Mr. Manprit Singh Randhawa	CFO, Secretary & Director	261.48k	N/A	1983
Laura Bey	Head of Formulations	N/A	N/A	N/A
Ms. Melissa Greenwell	Group Financial Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

Corporate governance

SkinBioTherapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.